Skip to content
Gene editing iPSCs

Gene editing iPSCs

Developing a robust pipeline for high throughput CRISPR/Cas-mediated gene editing in human induced pluripotent stem cells

Human induced pluripotent stem cell (hiPSC) technology has propelled the stem cell biology field; the ability of iPSCs to give rise to almost any cell type in the body offers opportunity for modelling diseases, drug discovery and cell therapy development. The capacity to genetically define iPSC-derived human disease models using CRISPR/Cas endonucleases significantly enhances their potential application. We have previously developed an automated pipeline to generate other genetically modified mammalian cell lines in a high throughput manner. We aimed to adapt this pipeline for CRISPR/Cas mediated gene editing of iPSCs to meet an increasing demand for custom iPSC manufacture and generation of complex disease models. Gene editing pluripotent stem cells can be challenging due to their sensitivity to spontaneous differentiation and their reported low editing efficiency. Therefore, we set out to develop an improved iPSC gene editing protocol, which would deliver an appropriate balance between efficiency and maintained cellular homeostasis.

Download the resource to read on...

We use cookies to give you the best experience of using this website. By continuing to use this site, you accept our use of cookies. Please read our Cookie Policy for more information.

Our single technology platform that fully connects our smart labs with our customer service proposition.


Connex revolutionises DNA design, optimization and assembly by ensuring the highest levels of quality control, efficiency and project management available for any client.

OXGENE has fully integrated all its smart labs and robotic production processes within a single technology platform that allows real-time project updates for our customers.